復宏漢霖(02696.HK)與PALLEON簽訂產品合作及許可協議
復宏漢霖(02696.HK)公布,與Palleon訂立合作及許可協議,據此,雙方同意基於各自專有技術和專利,就Palleon的產品雙功能HER2-唾液酸(酉每)融合蛋白,及共同開發的另一個腫瘤相關靶點-唾液酸(酉每)雙功能融合蛋白用於人類疾病治療的全球合作開發及於各自許可區域內的生產及商業化作出約定。
按合作協議,公司將向Palleon支付首付款400萬美元:及就兩款產品支付開發里程碑款不超過9,652萬美元、銷售里程碑款不超過1億美元,以及按年度淨銷售額8%-12%計的特許權使用費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.